Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Positron emission tomography/computerized tomography in lung cancer.

Literature DB >> 24914421

Positron emission tomography/computerized tomography in lung cancer.

Abstract

Positron emission tomography (PET) using 2-(18F)-flouro-2-deoxy-D-glucose (FDG) has emerged as a useful tool in the clinical work-up of lung cancer. This review article provides an overview of applications of PET in diagnosis, staging, treatment response evaluation, radiotherapy planning, recurrence assessment and prognostication of lung cancer.

Entities: Chemical Disease

Keywords: Positron emission tomography (PET); lung cancer; prognosis; radiotherapy planning; solitary pulmonary nodule (SPN); staging; therapy response

Year: 2014 PMID： 24914421 PMCID： PMC4032918 DOI： 10.3978/j.issn.2223-4292.2014.03.05

Source DB: PubMed Journal: Quant Imaging Med Surg ISSN： 2223-4306

107 in total

Review 1. Seeking a home for a PET, part 1: Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses.

Authors: Frank C Detterbeck; Steven Falen; M Patricia Rivera; Jan S Halle; Mark A Socinski
Journal: Chest Date: 2004-06 Impact factor: 9.410

2. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer.

Authors: Jong-Ryool Oh; Ji-Hyoung Seo; Ari Chong; Jung-Joon Min; Ho-Chun Song; Young-Chul Kim; Hee-Seung Bom
Journal: Eur J Nucl Med Mol Imaging Date: 2012-01-21 Impact factor: 9.236

3. MR imaging of pleural effusions.

Authors: S D Davis; C I Henschke; D F Yankelevitz; P T Cahill; Y Yi
Journal: J Comput Assist Tomogr Date: 1990 Mar-Apr Impact factor: 1.826

4. A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.

Authors: M E R O'Brien; J S Myerson; J I G Coward; M Puglisi; L Trani; A Wotherspoon; B Sharma; G Cook; S Ashley; R Gunapala; S Chua; S Popat
Journal: Eur J Cancer Date: 2011-11-24 Impact factor: 9.162

5. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma.

Authors: V Ahuja; R E Coleman; J Herndon; E F Patz
Journal: Cancer Date: 1998-09-01 Impact factor: 6.860

6. Cancer trends and incidence and mortality patterns in Turkey.

Authors: Hakki Hakan Yılmaz; Nuray Yazıhan; Dilara Tunca; Arzu Sevinç; Emire Özen Olcayto; Nejat Ozgül; Murat Tuncer
Journal: Jpn J Clin Oncol Date: 2010-06-17 Impact factor: 3.019

7. F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection.

Authors: S M Bakheet; M Saleem; J Powe; A Al-Amro; S G Larsson; Z Mahassin
Journal: Clin Nucl Med Date: 2000-04 Impact factor: 7.794

8. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

Authors: R Rosell; J Gómez-Codina; C Camps; J Maestre; J Padille; A Cantó; J L Mate; S Li; J Roig; A Olazábal
Journal: N Engl J Med Date: 1994-01-20 Impact factor: 91.245

Review 9. Noninvasive staging of non-small cell lung cancer: a review of the current evidence.

Authors: Eric M Toloza; Linda Harpole; Douglas C McCrory
Journal: Chest Date: 2003-01 Impact factor: 9.410

10. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria.

Authors: D Ziai; T Wagner; A El Badaoui; A Hitzel; J B Woillard; B Melloni; J Monteil
Journal: Cancer Imaging Date: 2013-03-05 Impact factor: 3.909

12 in total

1. Evidence based imaging strategies for solitary pulmonary nodule.

Authors: Yi-Xiang J Wang; Jing-Shan Gong; Kenji Suzuki; Sameh K Morcos
Journal: J Thorac Dis Date: 2014-07 Impact factor: 2.895

Review 2. The role of positron emission tomography in the diagnosis, staging and response assessment of non-small cell lung cancer.

Authors: Sara Volpi; Jason M Ali; Angela Tasker; Adam Peryt; Giuseppe Aresu; Aman S Coonar
Journal: Ann Transl Med Date: 2018-03

10. Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging.

Authors: Fu-Li Wang; Ye-Ying Tan; Xiang-Min Gu; Tian-Ran Li; Guang-Ming Lu; Gang Liu; Tian-Long Huo
Journal: Chin Med J (Engl) Date: 2016-12-20 Impact factor: 2.628

Positron emission tomography/computerized tomography in lung cancer.

Review 1. Seeking a home for a PET, part 1: Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses.

2. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer.

3. MR imaging of pleural effusions.

4. A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.

5. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma.

6. Cancer trends and incidence and mortality patterns in Turkey.

7. F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection.

8. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

Review 9. Noninvasive staging of non-small cell lung cancer: a review of the current evidence.

10. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria.

1. Evidence based imaging strategies for solitary pulmonary nodule.

Review 2. The role of positron emission tomography in the diagnosis, staging and response assessment of non-small cell lung cancer.

Review 3. PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies.

Review 4. Present and future roles of FDG-PET/CT imaging in the management of lung cancer.

5. Prognostic significance of FoxM1 expression in non-small cell lung cancer.

6. Appropriateness criteria of FDG PET/CT in oncology.

Review 7. PET/CT imaging in lung cancer: indications and findings.

8. Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer.

9. Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging.

10. Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging.